Clinical Trial Update: A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC) [Phase 2]

View source ↗

Summary

Phase II study evaluating pemetrexed plus gemcitabine in metastatic/recurrent head and neck squamous cell carcinoma; the trial completed and results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-03-05